Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023
News provided byHumacyte, Inc
Sep 18, 2023, 4:05 PM ET
DURHAM, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced it will host an in-person KOL event on Wednesday, September 20, 2023 at 3:00pm ET at The New York EDITION Hotel.
The event will feature Michael Curi, MD, MPA (Rutgers New Jersey Medical School) and his patient Devin Barnett, who will discuss the recently announced top line clinical data from the Humacyte Phase 2/3 V005 vascular trauma trial, the unmet clinical need in treating these injuries, and the use of the Human Acellular Vessel™ (HAV™) in repairing blood vessels.
The HAV is an off-the-shelf, universally implantable bioengineered human tissue, that is being studied in traumatic vascular injury and other vascular diseases. The HAV has received priority designation for the treatment of vascular trauma by the U.S. Department of Defense and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.
|Title:||KOL and Patient Perspectives: Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair|
|Location:||The New York EDITION (Flatiron District)|
|Date:||Wednesday, September 20, 2023|
|Time:||3:00 PM ET|
About Michael Curi, MD, MPA
Dr. Curi is a proud graduate of New Jersey Medical School and received his undergraduate degree from Lafayette College. Prior to medical school he obtained a Master’s Degree in Public Administration studying Health Policy & Management from New York University. He completed his surgical residency at University of Chicago where he spent an additional 2 years performing cutting-edge research into the treatment of vascular disease utilizing gene therapy and novel biological agents. He then completed an advanced fellowship in Vascular & Endovascular Surgery at Washington University in St. Louis, where he trained under Dr. Juan Parodi, inventor of the aortic stent graft. He has published many articles in leading vascular journals, authored chapters in surgical textbooks on aortic aneurysms, and has been nationally recognized for his work in vascular research. He is a member of the American College of Surgeons, Society of Vascular Surgery, Peripheral Vascular Surgical Society, and The Eastern Vascular Society and is an investigator on the V005 trial.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues with the potential to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial opportunity, a portfolio of HAVs, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm HAV for urgent arterial repair following extremity vascular trauma also has received RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the initiation, timing, progress, and results of our preclinical and clinical trials; the anticipated characteristics and performance of our HAVs; our ability to successfully complete, preclinical and clinical trials for our HAVs; the anticipated benefits of our HAVs relative to existing alternatives; the anticipated commercialization of our HAVs and our ability to manufacture at commercial scale; the implementation of our business model and strategic plans for our business; the timing or likelihood of regulatory filings and approvals; timing, scope, and rate of reimbursement for our HAVs; the outcome of our ongoing discussions with the FDA concerning the design of our ongoing V005 Phase 2/3 clinical trial, including determination of trial size, and the scope of any approved indication for our HAVs; and our estimated available market opportunity. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those included under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, filed by Humacyte with the SEC and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
NOTE: This content is not written by or endorsed by "WPRI", its advertisers, or Nexstar Media Inc.